HOUSTON , March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: Event: Cowen and Company 39th Annual Health Care Conference Presentation Date &

HOUSTON , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference: Event: Piper Jaffray Healthcare Conference Presentation Date & Time: Tuesday,

Data from Non-clinical Ovarian Cancer Study of AVB-500 and Proprietary GAS6 Biomarker Presented at the Society of Gynecologic Oncology’s 50th Annual Meeting HOUSTON , March 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that data

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase I study (32 subjects). The objective of this study is to evaluate the safety,

The combined company, Aravive, Inc. , to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018 , concurrent with a 1-for-6 reverse split of common shares HOUSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Aravive Biologics, Inc. and Versartis, Inc.

Aravive Biologics, Inc. and WuXi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously

Aravive Biologics, Inc. announced today that the company has completed both the single ascending dose and repeat dose portions of its Phase 1 study of AVB-S6-500 in healthy volunteers. The study met the safety and tolerability endpoints for the trial.

Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced two new appointments to the company’s scientific advisory board. Kimberly L. Blackwell, M.D., Vice President, Early Phase Oncology and

Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred to as Aravive-S6).  The study is being conducted in the United States

HOUSTON , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients